94 related articles for article (PubMed ID: 16007127)
1. JAK the trigger.
Mahon FX
Oncogene; 2005 Nov; 24(48):7125-6. PubMed ID: 16007127
[TBL] [Abstract][Full Text] [Related]
2. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.
Bousquet M; Quelen C; De Mas V; Duchayne E; Roquefeuil B; Delsol G; Laurent G; Dastugue N; Brousset P
Oncogene; 2005 Nov; 24(48):7248-52. PubMed ID: 16091753
[TBL] [Abstract][Full Text] [Related]
3. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
[TBL] [Abstract][Full Text] [Related]
4. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
Murati A; Gelsi-Boyer V; Adélaïde J; Perot C; Talmant P; Giraudier S; Lodé L; Letessier A; Delaval B; Brunel V; Imbert M; Garand R; Xerri L; Birnbaum D; Mozziconacci MJ; Chaffanet M
Leukemia; 2005 Sep; 19(9):1692-6. PubMed ID: 16034466
[No Abstract] [Full Text] [Related]
5. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
Bousquet M; Brousset P
Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
[No Abstract] [Full Text] [Related]
6. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma.
Adélaïde J; Pérot C; Gelsi-Boyer V; Pautas C; Murati A; Copie-Bergman C; Imbert M; Chaffanet M; Birnbaum D; Mozziconacci MJ
Leukemia; 2006 Mar; 20(3):536-7. PubMed ID: 16424865
[No Abstract] [Full Text] [Related]
7. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK
Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431
[TBL] [Abstract][Full Text] [Related]
8. The V617F JAK2 mutation and the myeloproliferative disorders.
Percy MJ; McMullin MF
Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
[TBL] [Abstract][Full Text] [Related]
9. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
10. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
11. Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.
Kronenwett R; Gräf T; Neumann F; Pechtel S; Steidl U; Diaz-Blanco E; Haas R
Leuk Res; 2006 Oct; 30(10):1323-4. PubMed ID: 16442619
[TBL] [Abstract][Full Text] [Related]
12. Implication of MAPK1/MAPK3 signalling pathway in t(8;9)(p22;24)/PCM1-JAK2 myelodysplastic/myeloproliferative neoplasms.
Masselli E; Mecucci C; Gobbi G; Carubbi C; Pierini V; Sammarelli G; Bonomini S; Prezioso L; Rossetti E; Caramatti C; Aversa F; Vitale M
Br J Haematol; 2013 Aug; 162(4):563-6. PubMed ID: 23701125
[No Abstract] [Full Text] [Related]
13. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.
Cirmena G; Aliano S; Fugazza G; Bruzzone R; Garuti A; Bocciardi R; Bacigalupo A; Ravazzolo R; Ballestrero A; Sessarego M
Cancer Genet Cytogenet; 2008 Jun; 183(2):105-8. PubMed ID: 18503828
[TBL] [Abstract][Full Text] [Related]
14. [Not just another kinase. New knowledge about myeloproliferative disease].
Bjerrum OW
Ugeskr Laeger; 2006 Sep; 168(39):3293. PubMed ID: 17032590
[No Abstract] [Full Text] [Related]
15. Molecular insights into the Philadelphia translocation.
Heisterkamp N; Groffen J
Hematol Pathol; 1991; 5(1):1-10. PubMed ID: 2050600
[TBL] [Abstract][Full Text] [Related]
16. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
[TBL] [Abstract][Full Text] [Related]
17. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
Berger R
Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
[No Abstract] [Full Text] [Related]
18. Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders.
Pesu M; O'Shea J; Hennighausen L; Silvennoinen O
Mol Interv; 2005 Aug; 5(4):211-5. PubMed ID: 16123535
[No Abstract] [Full Text] [Related]
19. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
Pargade V; Darnige L; Gaussem P
Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
[TBL] [Abstract][Full Text] [Related]
20. [New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia].
Matolcsy A
Orv Hetil; 2004 Dec; 145(52):2603-9. PubMed ID: 15724695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
